| Description |
1 online resource |
| Bibliography |
Includes bibliographical references and index. |
| Note |
Online resource; title from PDF title page (EBSCO, viewed June 7, 2019). |
| Summary |
The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industrýs productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. |
| Contents |
Machine generated contents note: Part I -- 1.Introduction: the remarkable success story of the development of bortezomib -- Brief story of the discovery and development of bortezomib -- Endnotes -- 2.Lessons from the development of bortezomib: the Core Model -- The Core Model and the academia-industry relationship -- Endnotes -- Part II -- 3.The "Core": when innovation meets leadership -- The biopharmaceutical industry and global health care -- The "Core" -- The Core and the pharmaceutical industry -- Endnotes -- 4."The Bridge": collaboration is the best catalyst to success -- Introduction -- Academia -- industry relationship -- Other types of Bridges -- Endnotes -- 5."The Periphery": the efficient use of underused societal resources -- Publicly funded Periphery -- Privately funded Periphery -- Public privately funded Periphery -- Summary: the Periphery and the Core Model -- Endnotes -- Part III -- 6.Biopharmaceutical intellectual property, financial interests, and the Core Model -- Patents -- Economic interests and patent cliff -- The Bayh -- Dole Act -- The Core Model and Intellectual Property Rights (IPRs) -- The Periphery and IPRs -- Endnotes -- 7.Global health care crisis, the pharmaceutical industry, and the Core Model -- The US health care crisis -- The pharmaceutical factor -- Current state of the pharmaceutical industry -- The Core Model -- Innovation deficit? -- Endnotes -- 8.The Core Model, innovation, economic growth, development, and policy-making -- Academia -- Public policy funding -- Pharmaceutical industry level -- Private foundations -- The developing world -- Endnotes -- Part IV -- 9.Conclusion: the Core Model: a novel economic theory -- Endnotes -- 10.Epilogue: the Core Model and other industries -- Endnotes. |
| Local Note |
Elsevier Elsevier ScienceDirect Open Access eBooks |
| Subject |
Pharmaceutical industry.
|
|
Medical care.
|
|
World health.
|
|
BUSINESS & ECONOMICS -- Industries -- General.
|
|
Medical care. (OCoLC)fst01013753
|
|
Pharmaceutical industry. (OCoLC)fst01060129
|
|
World health. (OCoLC)fst01181338
|
| ISBN |
9780128142943 (electronic book) |
|
0128142944 (electronic book) |
|
9780128142936 |
|
